400 results on '"Woźniak, Agnieszka"'
Search Results
2. Potentially actionable targets in synovial sarcoma: A tissue microarray study
3. Effectiveness of lasers and aPDT in elimination of intraoral halitosis: a systematic review based on clinical trials
4. Metabolomic and transcriptomic response to imatinib treatment of gastrointestinal stromal tumour in xenograft-bearing mice
5. Machine learning for rhabdomyosarcoma histopathology
6. The Effects of Lead and Cross-Talk Between Lead and Pea Aphids on Defence Responses of Pea Seedlings.
7. Synthesis, structure, properties and antimicrobial activity of para trifluoromethyl phenylboronic derivatives
8. Acidity Constants of Boronic Acids as Simply as Possible: Experimental, Correlations, and Prediction
9. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE
10. Equilibria in the 3-(trifluoromethyl)phenylboronic acid - boroxine system. Solubility of the acid and its cyclic esters in organic solvents
11. Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA”
12. Fish Consumption Frequency in the Adult Population in Poland.
13. Tetrabromobisphenol A, terabromobisphenol S and other bromophenolic flame retardants cause cytotoxic effects and induce oxidative stress in human peripheral blood mononuclear cells (in vitro study)
14. Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors
15. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’
16. The influence of ortho-substituents on the properties of phenylboronic acids
17. Synthesis, characterization and electrochemical properties of 3-ferrocenylbenzoxaboroles
18. Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors
19. Antifungal activity and tautomeric cyclization equilibria of formylphenylboronic acids
20. Oxidative stress links response to lead and Acyrthosiphon pisum in Pisum sativum L.
21. Synthesis and structural elucidation of novel antifungal N-(fluorophenyl)piperazinyl benzoxaboroles and their analogues
22. Structures and properties of trifluoromethylphenylboronic acids
23. The QEB questionnaire as an instrument to examine opinions on food and nutrition and indicators of the quality of diet
24. OxLDL as a prognostic biomarker of plaque instability in patients qualified for carotid endarterectomy.
25. The impact of local wind and spatial conditions on geometry blade of wind turbine.
26. Defense responses of Thuja orientalis to infestation of anholocyclic species aphid Cinara tujafilina
27. Etiological factors of bloodstream infections in oncological Patients, who was hospitalized at the National Institute of Maria Skłodowska-Curie – National Research Institute in Warsaw in 2020-2022
28. The protective effects of PCSK9 inhibitors on DNA damage in peripheral blood mononuclear cells in familial hypercholesterolemic patients
29. Spectroscopic insight into supramolecular assemblies of boric acid derivatives and β-cyclodextrin
30. Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy
31. Polymorphisms in the Von Hippel–Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors
32. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial
33. Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting
34. The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 ‘CREATE’
35. Discovering simple phenylboronic acid and benzoxaborole derivatives for experimental oncology – phase cycle-specific inducers of apoptosis in A2780 ovarian cancer cells
36. Meta-Isobutoxy Phenylboronic Acid for Nanoscale Multi-Stimuli-Responsive Low-Molecular-Weight Hydrogelator
37. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial
38. Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial
39. The Influence of Lead and Acyrthosiphon pisum (Harris) on Generation of Pisum sativum Defense Signaling Molecules and Expression of Genes Involved in Their Biosynthesis
40. Fluoro-substituted 2-formylphenylboronic acids: Structures, properties and tautomeric equilibria
41. Targeted Therapy in Gastrointestinal Stromal Tumors
42. The effect of lipid-lowering therapies on the pro-inflammatory and anti-inflammatory properties of vascular endothelial cells
43. Hip muscle strength and static balance in patients with snapping hip syndrome – a pilot study
44. Novel 2,6-disubstituted phenylboronic compounds – Synthesis, crystal structures, solution behaviour and reactivity
45. The influence of fluorine position on the properties of fluorobenzoxaboroles
46. Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models
47. Diversified self-association through O–H⋯O hydrogen bonds in crystals of formylphenylboronic acid isomers
48. Neuroblastic Tumors – Status and Role of HER Family Receptors
49. Severe COVID-19 classified by simple covid risk index is associated with higher levels of advanced oxidation protein products and 8-hydroxy 2 deoxyguanosine
50. Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.